- Stocks
- Healthcare
- NYSEAMERICAN: PLX

Price (delayed)

$1.46

Market cap

$106.51M

P/E Ratio

10.43

Dividend/share

N/A

EPS

$0.14

Enterprise value

$112.11M

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to

PLX's net income has soared by 159% year-on-year and by 19% since the previous quarter

PLX's EPS has surged by 138% year-on-year and by 40% since the previous quarter

The gross profit has surged by 73% year-on-year but it has declined by 3.4% since the previous quarter

Protalix BioTherapeutics's quick ratio has decreased by 49% QoQ but it has increased by 34% YoY

What are the main financial stats of PLX

Market
Valuations
Earnings

Shares outstanding

72.95M

Market cap

$106.51M

Enterprise value

$112.11M

Price to earnings (P/E)

10.43

Price to book (P/B)

2.73

Price to sales (P/S)

1.66

EV/EBIT

7.61

EV/EBITDA

7.05

EV/Sales

1.76

Revenue

$63.63M

EBIT

$14.74M

EBITDA

$15.89M

Free cash flow

-$8.64M

Per share
Balance sheet
Liquidity

EPS

$0.14

Free cash flow per share

-$0.12

Book value per share

$0.53

Revenue per share

$0.88

TBVPS

$1.21

Total assets

$87.57M

Total liabilities

$49.32M

Debt

$26.01M

Equity

$38.25M

Working capital

$29.26M

Debt to equity

0.68

Current ratio

1.67

Quick ratio

1.15

Net debt/EBITDA

0.35

Margins
Efficiency
Dividend

EBITDA margin

25%

Gross margin

74%

Net margin

16.7%

Operating margin

21.3%

Return on assets

14.2%

Return on equity

62.8%

Return on invested capital

35.1%

Return on capital employed

33.3%

Return on sales

23.2%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Protalix BioTherapeutics stock price performed over time

Intraday

-3.31%

1 week

2.1%

1 month

-9.88%

1 year

32.73%

YTD

6.57%

QTD

-12.05%

How have Protalix BioTherapeutics's revenue and profit performed over time

Revenue

$63.63M

Gross profit

$47.1M

Operating income

$13.58M

Net income

$10.62M

Gross margin

74%

Net margin

16.7%

Protalix BioTherapeutics's operating income has surged by 184% YoY and by 10% QoQ

The operating margin has soared by 162% YoY and by 16% from the previous quarter

PLX's net income has soared by 159% year-on-year and by 19% since the previous quarter

PLX's net margin has soared by 145% YoY and by 27% from the previous quarter

What is Protalix BioTherapeutics's growth rate over time

What is Protalix BioTherapeutics stock price valuation

P/E

10.43

P/B

2.73

P/S

1.66

EV/EBIT

7.61

EV/EBITDA

7.05

EV/Sales

1.76

PLX's EPS has surged by 138% year-on-year and by 40% since the previous quarter

Protalix BioTherapeutics's revenue has increased by 34% YoY but it has decreased by 6% from the previous quarter

PLX's price to sales (P/S) is 18% lower than its last 4 quarters average of 2.1 but 8% higher than its 5-year quarterly average of 1.6

How efficient is Protalix BioTherapeutics business performance

PLX's return on sales has surged by 172% year-on-year and by 20% since the previous quarter

The ROA has soared by 152% YoY and by 7% from the previous quarter

Protalix BioTherapeutics's return on equity has shrunk by 69% QoQ

The return on invested capital has increased by 10% since the previous quarter

What is PLX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for PLX.

How did Protalix BioTherapeutics financials performed over time

PLX's total assets is 78% greater than its total liabilities

PLX's total assets has surged by 54% year-on-year

Protalix BioTherapeutics's quick ratio has decreased by 49% QoQ but it has increased by 34% YoY

PLX's debt is 32% less than its equity

The debt to equity has surged by 124% year-on-year

PLX's debt is down by 22% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.